Literature DB >> 26789877

Prognostic Subgroups among Patients with Stage II Colon Cancer.

C Richard Boland1, Ajay Goel.   

Abstract

Colon cancer has traditionally been treated surgically. However, many cases of colon cancer are systemic at the time of diagnosis, and apparently curative surgery is followed at a later date by tumor recurrence as a consequence of circulating tumor cells before the surgery. Adjuvant medical therapies are designed to prevent recurrences after surgical resection. The current standard for clinical prognostication relies principally on pathological staging. In early-stage colon cancers (stages I and II), all the tumor is contained within the wall of the colon. Less than 10% of patients with stage I disease have a recurrence, and adjuvant chemotherapy is . . .

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26789877      PMCID: PMC4852473          DOI: 10.1056/NEJMe1514353

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  9 in total

Review 1.  Systemic therapy for colorectal cancer.

Authors:  Jeffrey A Meyerhardt; Robert J Mayer
Journal:  N Engl J Med       Date:  2005-02-03       Impact factor: 91.245

2.  TFAP2E-DKK4 and chemoresistance in colorectal cancer.

Authors:  Matthias P A Ebert; Marc Tänzer; Benjamin Balluff; Elke Burgermeister; Antje Karen Kretzschmar; David J Hughes; Reimo Tetzner; Catherine Lofton-Day; Robert Rosenberg; Anke C Reinacher-Schick; Karsten Schulmann; Andrea Tannapfel; Ralf Hofheinz; Christoph Röcken; Gisela Keller; Rupert Langer; Katja Specht; Rainer Porschen; Jan Stöhlmacher-Williams; Tibor Schuster; Philipp Ströbel; Roland M Schmid
Journal:  N Engl J Med       Date:  2012-01-05       Impact factor: 91.245

3.  Risk assessment in Stage II colorectal cancer.

Authors:  John L Marshall
Journal:  Oncology (Williston Park)       Date:  2010-01       Impact factor: 2.990

4.  Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains.

Authors:  Peter J Kneuertz; George J Chang; Chung-Yuan Hu; Miguel A Rodriguez-Bigas; Cathy Eng; Eduardo Vilar; John M Skibber; Barry W Feig; Janice N Cormier; Y Nancy You
Journal:  JAMA Surg       Date:  2015-05       Impact factor: 14.766

Review 5.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

Authors:  Al B Benson; Deborah Schrag; Mark R Somerfield; Alfred M Cohen; Alvaro T Figueredo; Patrick J Flynn; Monika K Krzyzanowska; Jean Maroun; Pamela McAllister; Eric Van Cutsem; Melissa Brouwers; Manya Charette; Daniel G Haller
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

6.  Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.

Authors:  Jia-Xing Zhang; Wu Song; Zhen-Hua Chen; Jin-Huan Wei; Yi-Ji Liao; Jian Lei; Ming Hu; Geng-Zhen Chen; Bing Liao; Jian Lu; Hong-Wei Zhao; Wei Chen; Yu-Long He; Hui-Yun Wang; Dan Xie; Jun-Hang Luo
Journal:  Lancet Oncol       Date:  2013-11-13       Impact factor: 41.316

Review 7.  Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.

Authors:  Yoshinaga Okugawa; William M Grady; Ajay Goel
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

Review 8.  Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.

Authors:  John M Carethers; Barbara H Jung
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

9.  Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up.

Authors:  Cari Lewis; Pengcheng Xun; Ka He
Journal:  Support Care Cancer       Date:  2015-09-09       Impact factor: 3.603

  9 in total
  12 in total

1.  Better survival of right-sided than left-sided stage II colon cancer: a propensity scores matching analysis based on SEER database.

Authors:  Shuanhu Wang; Xinxin Xu; Jiajia Guan; Rui Huo; Mulin Liu; Congqiao Jiang; Wenbin Wang
Journal:  Turk J Gastroenterol       Date:  2020-11       Impact factor: 1.852

2.  Macroscopic serosal invasion and small tumor size as independent prognostic factors in stage IIA colon cancer.

Authors:  Soo Young Lee; Chang Hyun Kim; Young Jin Kim; Hyeong Rok Kim
Journal:  Int J Colorectal Dis       Date:  2018-04-28       Impact factor: 2.571

3.  MicroRNA-421 Inhibits Apoptosis by Downregulating Caspase-3 in Human Colorectal Cancer.

Authors:  Yifan Zhou; Xiaowen Cheng; Yufeng Wan; Tingting Chen; Qing Zhou; Zhengguang Wang; Huaqing Zhu
Journal:  Cancer Manag Res       Date:  2020-08-21       Impact factor: 3.989

4.  The prognostic yield of biomarkers harvested in chemotherapy-naive stage II colon cancer: can we separate the wheat from the chaff?

Authors:  Martin M Watson; Kjetil Søreide
Journal:  Mol Med       Date:  2016-05-04       Impact factor: 6.354

5.  Prothrombin time (PT) and CEA as prognostic predictive biomarkers for postoperative recurrence after curative resection in patients with stage I-III colorectal cancer: a retrospective cohort study.

Authors:  Lulu Ma; Wenya Li; Ningquan Liu; Zhijie Ding; Jianchun Cai; Yiyao Zhang
Journal:  Updates Surg       Date:  2022-03-24

6.  Stromal Expression of Vimentin Predicts the Clinical Outcome of Stage II Colorectal Cancer for High-Risk Patients.

Authors:  Li-Guo Liu; Xue-Bing Yan; Ru-Ting Xie; Zhi-Ming Jin; Yi Yang
Journal:  Med Sci Monit       Date:  2017-06-14

7.  Homeobox protein CDX2 as a prognostic biomarker in solid malignancies: a meta-analysis.

Authors:  Jingsheng Yuan; Zhijie Yin; Kaixiong Tao; Guobing Wang; Jinbo Gao
Journal:  Oncotarget       Date:  2017-09-11

8.  Prognostic value of a hypoxia-related microRNA signature in patients with colorectal cancer.

Authors:  Yongmei Yang; Ailin Qu; Qi Wu; Xin Zhang; Lili Wang; Chen Li; Zhaogang Dong; Lutao Du; Chuanxin Wang
Journal:  Aging (Albany NY)       Date:  2020-01-11       Impact factor: 5.682

9.  High fascin-1 expression in colorectal cancer identifies patients at high risk for early disease recurrence and associated mortality.

Authors:  Athanasios Tampakis; Ekaterini-Christina Tampaki; Afrodite Nonni; Ioannis D Kostakis; Alberto Posabella; Konstantinos Kontzoglou; Markus von Flüe; Evangelos Felekouras; Gregory Kouraklis; Nikolaos Nikiteas
Journal:  BMC Cancer       Date:  2021-02-12       Impact factor: 4.430

10.  GLUT3 induced by AMPK/CREB1 axis is key for withstanding energy stress and augments the efficacy of current colorectal cancer therapies.

Authors:  Weixing Dai; Ye Xu; Shaobo Mo; Qingguo Li; Jun Yu; Renjie Wang; Yanlei Ma; Yan Ni; Wenqiang Xiang; Lingyu Han; Long Zhang; Sanjun Cai; Jun Qin; Wen-Lian Chen; Wei Jia; Guoxiang Cai
Journal:  Signal Transduct Target Ther       Date:  2020-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.